Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovotech ( (TSE:IOT) ) has shared an announcement.
Innovotech reported a strong 2025, with annual revenue rising to $4.53 million, more than double the prior year, driven by the full-year contribution of Keystone Labs and steady demand for antimicrobial contract research, analytical chemistry, GMP microbial testing, and stability testing services. The company posted a modest net income of $88,634 while prioritizing investments in staffing, lab capacity, sales capabilities, and R&D, and ended the year with a solid cash position and higher shareholders’ equity, leaving it well positioned to pursue continued organic growth and strategic initiatives.
More about Innovotech
Innovotech Inc. is a diversified life sciences services and technology company specializing in applied microbiology, analytical chemistry, and microbial testing for regulated healthcare markets. The company is recognized for its expertise in biofilm science and antimicrobial testing, operating ISO-certified and GMP-accredited labs that support medical device, pharmaceutical, and industrial product development across multiple geographies.
Average Trading Volume: 26,475
Technical Sentiment Signal: Sell
Current Market Cap: C$8.71M
For an in-depth examination of IOT stock, go to TipRanks’ Overview page.